These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1544830)

  • 1. Bioreductive mechanisms.
    Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):631-7. PubMed ID: 1544830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioreductive therapies: an overview of drugs and their mechanisms of action.
    Rauth AM; Melo T; Misra V
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioreductive drugs in cancer therapy.
    Stratford IJ
    BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioreductive therapy.
    Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1992; 22(4):685-7. PubMed ID: 1544837
    [No Abstract]   [Full Text] [Related]  

  • 5. Bioreductive prodrugs for cancer therapy.
    Seddon B; Kelland LR; Workman P
    Methods Mol Med; 2004; 90():515-42. PubMed ID: 14657582
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
    Lee AE; Wilson WR
    Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel multifunctional 2-nitroimidazole-based bioreductive linker and its application in hypoxia-activated prodrugs.
    Huang Y; Jin C; Yu J; Wang L; Lu W
    Bioorg Chem; 2020 Aug; 101():103975. PubMed ID: 32474180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs.
    Fielden EM; Adams GE; Cole S; Naylor MA; O'Neill P; Stephens MA; Stratford IJ
    Int J Radiat Oncol Biol Phys; 1992; 22(4):707-11. PubMed ID: 1544842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioreductive drugs for cancer therapy: the search for tumor specificity.
    Adams GE; Stratford IJ
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):231-8. PubMed ID: 8195012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Oxygen effect: an old new target?].
    Lartigau E; Dewas S; Gras L
    Cancer Radiother; 2008 Jan; 12(1):42-9. PubMed ID: 18261946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypoxic bioreductive agents: the possible immune and receptor-mediated mechanisms of antitumor action].
    Shchepetkin IA
    Eksp Klin Farmakol; 1999; 62(3):67-74. PubMed ID: 10439954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
    Minchinton AI; Lemmon MJ; Tracy M; Pollart DJ; Martinez AP; Tosto LM; Brown JM
    Int J Radiat Oncol Biol Phys; 1992; 22(4):701-5. PubMed ID: 1544841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
    Wilson WR; Tercel M; Anderson RF; Denny WA
    Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting tumors with hypoxia-activated cytotoxins.
    Ahn GO; Brown M
    Front Biosci; 2007 May; 12():3483-501. PubMed ID: 17485316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of hypoxia selective cytotoxins for cancer treatment: an update.
    Cerecetto H; González M; Lavaggi ML
    Med Chem; 2006 May; 2(3):315-27. PubMed ID: 16948479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypoxia: a therapeutic target].
    Fernández-Braña M
    Clin Transl Oncol; 2005 Dec; 7(11):475-6. PubMed ID: 16373057
    [No Abstract]   [Full Text] [Related]  

  • 18. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine.
    Wilson WR; Siim BG; Denny WA; van Zijl PL; Taylor ML; Chambers DM; Roberts PB
    Radiat Res; 1992 Sep; 131(3):257-65. PubMed ID: 1438685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.
    Workman P
    Oncol Res; 1994; 6(10-11):461-75. PubMed ID: 7620214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.